|Articles|April 1, 2004
Does it impact survival?
Washington - Sentinel lymph node biopsy may not be standard of care today in the management of patients with early melanoma and clinically negative nodes, but neither should it be considered an experimental technique, said Gary S. Rogers, M.D., at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus
2
LEVEL UP Study Shows Benefits of Switching From Dupilumab to Upadacitinib in AD
3
Case-Based Perspectives on Biologic Treatment for Hidradenitis Suppurativa
4
The Aesthetic Edge: January 2026
5















